Genenta Science S.p.A.

NasdaqCM GNTA

Genenta Science S.p.A. Return on Capital Employed (ROCE) for the Trailing 12 Months (TTM) ending December 31, 2023

Genenta Science S.p.A. Return on Capital Employed (ROCE) is NA for the Trailing 12 Months (TTM) ending December 31, 2023. Return on capital employed assesses profitability against invested capital; higher ROCE signals efficient capital use.

Key data

Date	Return on Capital Employed (ROCE)	Interest Coverage Ratio	Debt to Equity Ratio	Return on Common Equity

NasdaqCM: GNTA

Genenta Science S.p.A.

CEO	Mr. Pierluigi Paracchi
IPO Date	Dec. 15, 2021
Location	Italy
Headquarters	Via Olgettina No. 58
Employees	14
Sector	Health Care
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. The company's lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. It is also developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. The company was incorporated in 2014 and is headquartered in Milan, Italy.

Key trends

Past 5 years